版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
GettingBloodPressuretoGoalRulesofThree:3drugs3months3behaviors(Activity-Diet-ControlofTobaccoandAlcohol)3Partners(Patient–Family–Provider)GettingBloodPressuretoGoal1ThisprogramwassponsoredbytheNationalKidneyFoundationofMichigan(NKFM)andtheMichiganDepartmentofCommunityHealth(MDCH).FundingwasprovidedbyagenerousgrantfromNKFMandMDCHandvariouspharmacompanies.ContinuingMedicalEducationcreditisprovidedbyWayneStateUniversitySchoolofMedicineTheprogramwasdevelopedandpreparedby:
DianeLevine,MDWayneStateUniversitySilasNorman,MD,UniversityofMichiganRosalindPeters,PhD,RN,WayneStateUniversitySusanSteigerwalt,MD,St.JohnHospitalWithinputfromtheHypertensionExpertGroupofNKFMandtheexpertiseandcreativityofitsmemberswithspecialthankstoVelmaTheisenandLindaSmithWheelockACSW,MSBAThisprogramwassponsoredby2ConflictofInterestIndividualSpeakerstoAddtheirinformationpriortopresenting
ConflictofInterestIndividual3【高血压英文课件】-Getting-Blood-Pressure-to-Goal4【高血压英文课件】-Getting-Blood-Pressure-to-Goal5MajorityofUSHypertensivePatientsNotatSBPGoalof<140mmHgMajorityofUSHypertensivePa6UnacceptableBPControlRatesRequireIncreasedAwareness,MoreAggressiveTreatmentUnacceptableBPControlRates7SignificanceofHBPProblem50%ofhypertensivesareuncontrolled.UptohalfarenotreceivingpharmacologictreatmentAntihypertensivetherapycanStroke–30%CHF–40-50%CAD–10-20%CADEvents-~55%Mortality–10%~$1Billionindirectmedicalcosts/yearSignificanceofHBPProblem50%8CardiovascularMortalityRiskDoublesWithEach20/10mmHgBPIncrement*CardiovascularMortalityRisk9CV-RelatedMortalityRatesAreHigherinAfricanAmericansCV-RelatedMortalityRatesAre10CardiovascularEventsinTreatedHypertensiveDiabeticPatientsCardiovascularEventsinTreat11PreventingKidneyFailureAfricanAmericansinMichiganhavepoorerbloodpressurecontrolthanCaucasiansAfricanAmericansareatfivetimesgreaterriskofprogressiontoendstagerenaldiseaseBetterbloodpressurecontrolSLOWSPROGRESSIONofrenaldiseaseBPcontrolreducestheriskofstroke,MI,andCHFPreventingKidneyFailureAfric12FactorsContributingtoPoorBPControlPatientFactorsAgeRace/ethnicityObesityAccessNonadherenceKnowledgeCostComplextreatmentPt/ProviderCommunicationSecondaryHTNProviderFactorsMeasurementissuesLackofknowledge/DisagreementwithguidelinesConcernforsideeffectsNon-advancingofdrugsinasymptomaticpatientsResponsetopatientsconcernsovercomplexityoftreatmentLackoftimeFactorsContributingtoPoorB13MeasurementAccuracyAccuracyofofficemeasurementsManual–RegularlycalibratedWhite-CoatSyndromeHomeMonitoring
OmronHealthcareArm(notwrist)monitorGoalreadings<135/85MeasurementAccuracyAccuracyo14
MeasurementAccuracy*
PatientPosition:BacksupportedFeetonthefloorArmattheleveloftheheartNotalkingCuffSize–Mostadultsneedalargecuff(SeeCDandAHAwebsitefordetails)TaketwiceCheckorthostaticbloodpressure*CDprovidedtosupportreviewandstandardizationofBPmeasurement
MeasurementAccuracy*
Pa15MeasurementAccuracy:
OrthostaticHypotension20%prevalenceincommunitydwellingadultsoverage65IncreaseswithagePresentinyoungerpatientswithdiabetesorautonomicdysfunction“Iforthostasiscannotbecorrected,usestandingBPtoassessgoalBP”(JNC-7)MeasurementAccuracy:
Orthosta16JNC7:NewBPClassificationsJNC7:NewBPClassifications17JNC7RecommendedBPGoals<140and<90mmHg
Patientswithmostconditions<130and<80mmHgDiabetesMellitusCKDAlbuminuria>300mg/24hror>200mg/gurinarycreatinineeGFR<60ml/min/1.73m2SerumcreatininelevelsaloneoverestimatekidneyfunctionAssessandaddressothercardiovascularriskfactorsChobanianAVetal.JAMA.2003;289:2560-2572.JNC7RecommendedBPGoals<14018JNC7:ManagementofHypertensionbyBPClassificationJNC7:ManagementofHypertens19CommonProviderConcernswithGuidelineGoals
NonAcceptanceofBPgoalsResistancetoacceptSBPthresholdsNottreatingunlessSBP>160mmHgConcernsofincreasedcardiovascularriskwithexcessiveloweringofDBP(J-Curve)BelievethatmoretimeisneededtoreachgoalVALUE,
LANCET,2004:363:2022-2031CommonProviderConcernswith20Ruleof3
“MDBP”3
Months3
Drugs3
Behaviors
(activity-diet-alcoholandtobaccocontrol)3
Partners
(Patient–Family–Provider)Ruleof3
“MDBP”3Months21
ItMightTake3MonthsGettingBPtogoalin3monthsRequiresmultiplevisitsGettingtoGoalvisitschedule:MonthlyuntilgoalisreachedIncreasevisitfrequencyifStage2Increasevisitfrequencywithcomorbidconditions
Atgoal–followupvisitscheduleEvery3-6monthsdependingoncomorbiditiesCheckK+andCreatinine1-2x/year
ItMightTake3MonthsGetting22
DrugTherapyStepApproach:StartwithdiureticifnocontraindicationsAddACEICalciumChannelBlocker(CCB)Betablockers–butcautionMostpatientsrequire
multipledrugstoachievecontrol(average=3.5drugs)Usemultipledrugsif:BP20/10mmHgabovegoal(Stage22drugs)StandingBPabovegoalinpatientsoverage65orDMNotatgoalafter3months
DrugTherapyStepApproach:23MultipleAntihypertensiveAgentsAreNeededtoAchieveTargetBloodPressureMultipleAntihypertensiveAgen24DrugTreatment:DiureticsIfnocompellingindications(CHF,diabetes,CKD)Chlorthalidone(orotherthiazides)firstThenACEIorARBRememberBetaBlockersARENOTforprimarypreventionandareinferiortodiureticsasmonotherapyVigilantlypreventhypokalemiaSpironolactone/HCTZisagreatcombination!BringpatientsbackinoneweektocheckfordiureticinducedhypokalemiaWatchforhyponatremiaDrugTreatment:DiureticsIfno25DrugTreatment:ACEinhibitorsCheckElectrolytes,BUN,andCreatininepriortostartingRecheckK+andCreatinine1weekafterinitiationoftherapyGenericavailableBIDDosing:enalapril(5mgbid-20mgbid)captopril(12.5mgbid-50mgbid)DailyDosinglisinopril(5-40mgdaily)Sideeffects:Cough-switchtoARBifaffordableHyperkalemiaandacuterenalfailureAngioedemaDrugTreatment:ACEinhibitors26WhatHaveWeLearned?
TreatmentTreatmentoftheveryelderlydecreases strokeandCADbutdoesnotprolongsurvival(Lancet1999:353:793)Bestdrugsinrankorder:ChlorthalidoneACEinhibitorHCTZ(Hypertension2004;44:800)CCB
WhatHaveWeLearned?
Treatme27WhatHaveWeLearned?
TreatmentACEIandARBdecreasenewonsetofdiabetesby25%comparedtobetablockers(LIFE);23%comparedtoCCBs(VALUEtrial)NewonsetofdiabeteswhileundergoingtreatmentforhypertensionconfersthesameexcessCVriskaspreexistingdiabetes(Hypertension(2004)43p.963)WhatHaveWeLearned?
Treatme28WhatHaveWeLearned?
TreatmentMonotherapywithatenololisNOTasefficaciousasotherantihypertensivesfordecreasingCVriskdespiteequivalentBPcontrol(Lancet:2004:364:1684)BetablockersareinferiortodiureticsforbloodpressurecontrolandCVriskprotection(stroke,CHF)inolderpatients(MRCtrial,1990;JAMA
1998;279:1903-1907;INVEST:JAMA290:2805-2816;ASCOTTrial)WhatHaveWeLearned?
Treatme29CombinationTreatmentsLogical/additivecombinationsDiuretic+ACEIorARBDiuretic+BetaBlockerorsympatholyticsCCB+ACEIorARBDiuretic+BetaBlocker+vasodilatorDiuretic+CCBCombinationTreatmentsLogical30CombinationTreatmentsCombinationswithNOadditiveeffectBetaBlocker+ACEIVasodilators+CCBCombinationwithadditivesideeffectsBetaBlocker+clonidineorguanfacineBetaBlocker+verapamilordiltiazemClonidine/guanfacine+verapamilordiltiazemCombinationTreatmentsCombinat31Whenadding
Indifficulttocontrolpatients
ItTakes3DRUGS!ChoosealogicalADDITIVEcombinations:Diuretic+ACEI+CCBDiuretic+BBlocker+vasodilatorDiuretic+clonidine+vasodilatorWhenadding
32SpecialPopulationsDiabetesACEIorARBDiureticsareimportantadjuncttherapyBScontrolassociatedwithBPcontrolCKDACEIorARBareimportanttopreserverenalfunctionIfeGFR<50starttorsemideorfurosemidebidPostMIBetablockersACEIorARBCheckK+andCreatininepriortoinitiatingand1weekafterinitiatingACESpecialPopulationsDiabetes33
ItMightTake3MonthsButifnotatgoalby6monthsconsider:PatientreasonsfornonadherenceSleepApneaAlcoholoveruseDiabetesChronicKidneyDiseaseSecondarycausesConsultwithorrefertoHypertensionSpecialist
VALUE,LANCET,2004:363:2022-2031
ItMightTake3MonthsButif34SleepApneaUpto60%maleswithresistanthypertension(alsocommoninpostmenopausalfemales)Suspectdiagnosis-screenandreferPathophysiologyofhypertensionlikelySNSactivationSleepApneaUpto60%maleswit35
Lifestyle:ItTakes3BEHAVIORSExerciseDietControloftobaccoandalcohol
Lifestyle:ItTakes3BEHAVIO36Lifestyle:Exercise4-9mmHgSBPreduction30-45minutes/day/5-7days/weekAerobicactivity(e.g.briskwalking)WriteaprescriptionFavoritePatientSig40minutesofwalking5X/wk BPMD3333Lifestyle:Exercise4-9mmHgSBP37Lifestyle:DietWeightControl
5-20mmHgSBPreduction/10kgLowSodium(<2.4g)
2-8mmHgSBPreductionDASH8-14mmHgSBPreductionLifestyle:DietWeightControl38ControlofTobaccoandAlcoholSmokingCessationWriteprescriptionAlcoholModeration<2alcoholicdrinks/day–men<1alcoholicdrink/day–women2-4mmHgreductioninSBPAccessforothersubstancesControlofTobaccoandAlcohol39Partners:Ittakes3PartnersPatientFamilyProviderProvider/PatientRelationshipKeyPartners:Ittakes3PartnersP40ThePatient:Participationiscrucial
Describethejourney“Thisisaseriousdisease”“Iwillneedtoseeyouevery4-6weeks”“Thisisyourgoal<140/90(or130/80)”“Achievingyourgoalisimportantbecauseitlowersyourriskof…Sharegoalsetting“Let’ssetsomegoals“Thishowcanyouhelp“Whatareyouwillingtodo?“Weareateam—Patient,provider,“family”Ifwedonotachieveyourgoals…ThePatient:Participationis41Partners:PatientsPatientnon-adherencetotherapyLackofconcernifasymptomaticFeel“better”withhigherBPDon’tworryabout“touch”ofhighBPMistrustofhealthcareprovidersandhealthcaresystemImprovedadherencewithIncreasedcontactwithprovidersSelf/homeBPmeasurement-OMRONarm,usuallyLARGEADULTcuff(Bladderencircling80%arm)Useofpatientrecordtokeeptrackofinfluenceoffactors(e.g.diet)onBPPartners:PatientsPatientnon-42Partners:
“Family”,Friends,CommunityInvolve“family”wheneverpossibleEssentialforlifestylemodificationBefamiliarwithcommunityresourcesPartners:
“Family”,Friends,43Partners:ProvidersFollowJNCandMQIC*GuidelinesDocumentGoalSchedulefrequentvisitstogettogoal
3monthstogoal!!!!ToolstogettogoaleGFRslideruletoassessrenalfunctionCollaborativepracticewithAPNsimprovescontrol*www.MQIC.orgPartners:ProvidersFollowJNC44ProviderStepsto
IncreaseAdherenceWritelifestyleprescriptionsConsidercostsofdrugs–genericswheneverpossibleSimplifydrugregimensDailytherapyorBIDAddresspatient’sunderstandingofthediseaseanditstreatmentTelephonefollowupsincreaseadherenceespeciallyfor“noshows”trytokeepthemintreatmentAdditionalfollowupasnegotiatedwithpatientOfficeRNorAPNwillincreaseBPcontrol(CollaborativePractice)ProviderStepsto
IncreaseAd45KeyPointsfromPresentation
MeasurementAccuracyisimportantDetermineGoalBP<140/90<130/80DMCKDFollowguidelinesRulesof3(MDBP)3
Months3
Drugs3
Behaviors3
PartnersKeyPointsfromPresentationM46HandoutsInformationcontainedonCDTonight’sslidepresentation–sharewithcolleaguesBPmeasurementprotocolMQICguidelinesNHLBIDASHdietinformationPatientHealthRecordPrescriptionpadsforexercise/lifestyleprescriptionsHandoutsInformationcontained47Questions?
Casesyou’dliketodiscuss?Questions?
Casesyou’dliket48GettingBloodPressuretoGoalRulesofThree:3drugs3months3behaviors(Activity-Diet-ControlofTobaccoandAlcohol)3Partners(Patient–Family–Provider)GettingBloodPressuretoGoal49ThisprogramwassponsoredbytheNationalKidneyFoundationofMichigan(NKFM)andtheMichiganDepartmentofCommunityHealth(MDCH).FundingwasprovidedbyagenerousgrantfromNKFMandMDCHandvariouspharmacompanies.ContinuingMedicalEducationcreditisprovidedbyWayneStateUniversitySchoolofMedicineTheprogramwasdevelopedandpreparedby:
DianeLevine,MDWayneStateUniversitySilasNorman,MD,UniversityofMichiganRosalindPeters,PhD,RN,WayneStateUniversitySusanSteigerwalt,MD,St.JohnHospitalWithinputfromtheHypertensionExpertGroupofNKFMandtheexpertiseandcreativityofitsmemberswithspecialthankstoVelmaTheisenandLindaSmithWheelockACSW,MSBAThisprogramwassponsoredby50ConflictofInterestIndividualSpeakerstoAddtheirinformationpriortopresenting
ConflictofInterestIndividual51【高血压英文课件】-Getting-Blood-Pressure-to-Goal52【高血压英文课件】-Getting-Blood-Pressure-to-Goal53MajorityofUSHypertensivePatientsNotatSBPGoalof<140mmHgMajorityofUSHypertensivePa54UnacceptableBPControlRatesRequireIncreasedAwareness,MoreAggressiveTreatmentUnacceptableBPControlRates55SignificanceofHBPProblem50%ofhypertensivesareuncontrolled.UptohalfarenotreceivingpharmacologictreatmentAntihypertensivetherapycanStroke–30%CHF–40-50%CAD–10-20%CADEvents-~55%Mortality–10%~$1Billionindirectmedicalcosts/yearSignificanceofHBPProblem50%56CardiovascularMortalityRiskDoublesWithEach20/10mmHgBPIncrement*CardiovascularMortalityRisk57CV-RelatedMortalityRatesAreHigherinAfricanAmericansCV-RelatedMortalityRatesAre58CardiovascularEventsinTreatedHypertensiveDiabeticPatientsCardiovascularEventsinTreat59PreventingKidneyFailureAfricanAmericansinMichiganhavepoorerbloodpressurecontrolthanCaucasiansAfricanAmericansareatfivetimesgreaterriskofprogressiontoendstagerenaldiseaseBetterbloodpressurecontrolSLOWSPROGRESSIONofrenaldiseaseBPcontrolreducestheriskofstroke,MI,andCHFPreventingKidneyFailureAfric60FactorsContributingtoPoorBPControlPatientFactorsAgeRace/ethnicityObesityAccessNonadherenceKnowledgeCostComplextreatmentPt/ProviderCommunicationSecondaryHTNProviderFactorsMeasurementissuesLackofknowledge/DisagreementwithguidelinesConcernforsideeffectsNon-advancingofdrugsinasymptomaticpatientsResponsetopatientsconcernsovercomplexityoftreatmentLackoftimeFactorsContributingtoPoorB61MeasurementAccuracyAccuracyofofficemeasurementsManual–RegularlycalibratedWhite-CoatSyndromeHomeMonitoring
OmronHealthcareArm(notwrist)monitorGoalreadings<135/85MeasurementAccuracyAccuracyo62
MeasurementAccuracy*
PatientPosition:BacksupportedFeetonthefloorArmattheleveloftheheartNotalkingCuffSize–Mostadultsneedalargecuff(SeeCDandAHAwebsitefordetails)TaketwiceCheckorthostaticbloodpressure*CDprovidedtosupportreviewandstandardizationofBPmeasurement
MeasurementAccuracy*
Pa63MeasurementAccuracy:
OrthostaticHypotension20%prevalenceincommunitydwellingadultsoverage65IncreaseswithagePresentinyoungerpatientswithdiabetesorautonomicdysfunction“Iforthostasiscannotbecorrected,usestandingBPtoassessgoalBP”(JNC-7)MeasurementAccuracy:
Orthosta64JNC7:NewBPClassificationsJNC7:NewBPClassifications65JNC7RecommendedBPGoals<140and<90mmHg
Patientswithmostconditions<130and<80mmHgDiabetesMellitusCKDAlbuminuria>300mg/24hror>200mg/gurinarycreatinineeGFR<60ml/min/1.73m2SerumcreatininelevelsaloneoverestimatekidneyfunctionAssessandaddressothercardiovascularriskfactorsChobanianAVetal.JAMA.2003;289:2560-2572.JNC7RecommendedBPGoals<14066JNC7:ManagementofHypertensionbyBPClassificationJNC7:ManagementofHypertens67CommonProviderConcernswithGuidelineGoals
NonAcceptanceofBPgoalsResistancetoacceptSBPthresholdsNottreatingunlessSBP>160mmHgConcernsofincreasedcardiovascularriskwithexcessiveloweringofDBP(J-Curve)BelievethatmoretimeisneededtoreachgoalVALUE,
LANCET,2004:363:2022-2031CommonProviderConcernswith68Ruleof3
“MDBP”3
Months3
Drugs3
Behaviors
(activity-diet-alcoholandtobaccocontrol)3
Partners
(Patient–Family–Provider)Ruleof3
“MDBP”3Months69
ItMightTake3MonthsGettingBPtogoalin3monthsRequiresmultiplevisitsGettingtoGoalvisitschedule:MonthlyuntilgoalisreachedIncreasevisitfrequencyifStage2Increasevisitfrequencywithcomorbidconditions
Atgoal–followupvisitscheduleEvery3-6monthsdependingoncomorbiditiesCheckK+andCreatinine1-2x/year
ItMightTake3MonthsGetting70
DrugTherapyStepApproach:StartwithdiureticifnocontraindicationsAddACEICalciumChannelBlocker(CCB)Betablockers–butcautionMostpatientsrequire
multipledrugstoachievecontrol(average=3.5drugs)Usemultipledrugsif:BP20/10mmHgabovegoal(Stage22drugs)StandingBPabovegoalinpatientsoverage65orDMNotatgoalafter3months
DrugTherapyStepApproach:71MultipleAntihypertensiveAgentsAreNeededtoAchieveTargetBloodPressureMultipleAntihypertensiveAgen72DrugTreatment:DiureticsIfnocompellingindications(CHF,diabetes,CKD)Chlorthalidone(orotherthiazides)firstThenACEIorARBRememberBetaBlockersARENOTforprimarypreventionandareinferiortodiureticsasmonotherapyVigilantlypreventhypokalemiaSpironolactone/HCTZisagreatcombination!BringpatientsbackinoneweektocheckfordiureticinducedhypokalemiaWatchforhyponatremiaDrugTreatment:DiureticsIfno73DrugTreatment:ACEinhibitorsCheckElectrolytes,BUN,andCreatininepriortostartingRecheckK+andCreatinine1weekafterinitiationoftherapyGenericavailableBIDDosing:enalapril(5mgbid-20mgbid)captopril(12.5mgbid-50mgbid)DailyDosinglisinopril(5-40mgdaily)Sideeffects:Cough-switchtoARBifaffordableHyperkalemiaandacuterenalfailureAngioedemaDrugTreatment:ACEinhibitors74WhatHaveWeLearned?
TreatmentTreatmentoftheveryelderlydecreases strokeandCADbutdoesnotprolongsurvival(Lancet1999:353:793)Bestdrugsinrankorder:ChlorthalidoneACEinhibitorHCTZ(Hypertension2004;44:800)CCB
WhatHaveWeLearned?
Treatme75WhatHaveWeLearned?
TreatmentACEIandARBdecreasenewonsetofdiabetesby25%comparedtobetablockers(LIFE);23%comparedtoCCBs(VALUEtrial)NewonsetofdiabeteswhileundergoingtreatmentforhypertensionconfersthesameexcessCVriskaspreexistingdiabetes(Hypertension(2004)43p.963)WhatHaveWeLearned?
Treatme76WhatHaveWeLearned?
TreatmentMonotherapywithatenololisNOTasefficaciousasotherantihypertensivesfordecreasingCVriskdespiteequivalentBPcontrol(Lancet:2004:364:1684)BetablockersareinferiortodiureticsforbloodpressurecontrolandCVriskprotection(stroke,CHF)inolderpatients(MRCtrial,1990;JAMA
1998;279:1903-1907;INVEST:JAMA290:2805-2816;ASCOTTrial)WhatHaveWeLearned?
Treatme77CombinationTreatmentsLogical/additivecombinationsDiuretic+ACEIorARBDiuretic+BetaBlockerorsympatholyticsCCB+ACEIorARBDiuretic+BetaBlocker+vasodilatorDiuretic+CCBCombinationTreatmentsLogical78CombinationTreatmentsCombinationswithNOadditiveeffectBetaBlocker+ACEIVasodilators+CCBCombinationwithadditivesideeffectsBetaBlocker+clonidineorguanfacineBetaBlocker+verapamilordiltiazemClonidine/guanfacine+verapamilordiltiazemCombinationTreatmentsCombinat79Whenadding
Indifficulttocontrolpatients
ItTakes3DRUGS!ChoosealogicalADDITIVEcombinations:Diuretic+ACEI+CCBDiuretic+BBlocker+vasodilatorDiuretic+clonidine+vasodilatorWhenadding
80SpecialPopulationsDiabetesACEIorARBDiureticsareimportantadjuncttherapyBScontrolassociatedwithBPcontrolCKDACEIorARBareimportanttopreserverenalfunctionIfeGFR<50starttorsemideorfurosemidebidPostMIBetablockersACEIorARBCheckK+andCreatininepriortoinitiatingand1weekafterinitiatingACESpecialPopulationsDiabetes81
ItMightTake3MonthsButifnotatgoalby6monthsconsider:PatientreasonsfornonadherenceSleepApneaAlcoholoveruseDiabetesChronicKidneyDiseaseSecondarycausesConsultwithorrefertoHypertensionSpecialist
VALUE,LANCET,2004:363:2022-2031
ItMightTake3MonthsButif82SleepApneaUpto60%maleswithresistanthypertension(alsocommoninpostmenopausalfemales)Suspectdiagnosis-screenandreferPathophysiologyofhypertensionlikelySNSactivationSleepApneaUpto60%maleswit83
Lifestyle:ItTakes3BEHAVIORSExerciseDietControloftobaccoandalcohol
Lifestyle:ItTakes3BEHAVIO84Lifestyle:Exercise4-9mmHgSBPreduction30-45minutes/day/5-7days/weekAerobicactivity(e.g.briskwalking)WriteaprescriptionFavoritePatientSig40minutesofwalking5X/wk BPMD3333Lifestyle:Exercise4-9mmHgSBP85Lifestyle:DietWeightControl
5-20mmHgSBPreduction/10kgLowSodium(<2.4g)
2-8mmHgSBPreductionDASH8-14mmHgSBPreductionLifestyle:DietWeightControl86ControlofTobaccoandAlcoholSmokingCessationWriteprescriptionAlcoholModeration<2alcoholicdrinks/day–men<1alcoholicdrink/day–women2-4mmHgreductioninSBPAccessforothersubstancesControlofTobaccoandAlcohol87Partners:Ittakes3PartnersPatientFamilyProviderProvider/Pa
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2025年甘肃会展中心有限责任公司招聘笔试参考题库含答案解析
- 2025版智慧城市运营项目融资协议合同范本3篇
- 2025年度个人小户型房产买卖及装修改造合同4篇
- 2025年个人森林抚育与更新承包合同4篇
- 2025年全球及中国医用协作机器人行业头部企业市场占有率及排名调研报告
- 2025-2030全球邻氯苯腈(氯化法)行业调研及趋势分析报告
- 2025-2030全球触控灯行业调研及趋势分析报告
- 2025版拖拉机销售与保险服务合同范本6篇
- 2025年度房产租赁合同(含租金调整及违约责任)3篇
- 2025年度个人设备租赁贷款合同范本7篇
- 2024年全国职业院校技能大赛高职组(研学旅行赛项)考试题库(含答案)
- 2025年温州市城发集团招聘笔试参考题库含答案解析
- 2025年中小学春节安全教育主题班会课件
- 2025版高考物理复习知识清单
- 计量经济学练习题
- 除数是两位数的除法练习题(84道)
- 2025年度安全检查计划
- 2024年度工作总结与计划标准版本(2篇)
- 全球半导体测试探针行业市场研究报告2024
- 反走私课件完整版本
- 2024年注册计量师-一级注册计量师考试近5年真题附答案
评论
0/150
提交评论